Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System.

Della Porta MG, Jackson CH, Alessandrino EP, Rossi M, Bacigalupo A, van Lint MT, Bernardi M, Allione B, Bosi A, Guidi S, Santini V, Malcovati L, Ubezio M, Milanesi C, Todisco E, Voso MT, Musto P, Onida F, Iori AP, Cerretti R, Grillo G, Molteni A, Pioltelli P, Borin L, Angelucci E, Oldani E, Sica S, Pascutto C, Ferretti V, Santoro A, Bonifazi F, Cazzola M, Rambaldi A.

Leukemia. 2017 Nov;31(11):2449-2457. doi: 10.1038/leu.2017.88. Epub 2017 Mar 21.

2.

Neurological Complications Involving the Central Nervous System After Allogeneic Hematopoietic Stem Cell Transplantation During a Period of Evolution in Transplant Modalities: A Cohort Analysis.

Colombo AA, Marchioni E, Diamanti L, Di Matteo AM, Baldanti F, Furione M, Cazzola M, Ferretti VV, Pascutto C, Alessandrino EP.

Transplantation. 2017 Mar;101(3):616-623. doi: 10.1097/TP.0000000000001257.

PMID:
27222935
3.

Independent prognostic impact of tumour-infiltrating macrophages in early-stage Hodgkin's lymphoma.

Gotti M, Nicola M, Lucioni M, Fiaccadori V, Ferretti V, Sciarra R, Costanza M, Bono E, Molo S, Maffi A, Croci GA, Varettoni M, Frigeni M, Pascutto C, Arcaini L, Bonfichi M, Paulli M, Cazzola M.

Hematol Oncol. 2017 Sep;35(3):296-302. doi: 10.1002/hon.2295. Epub 2016 Apr 6.

PMID:
27060262
4.

Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.

Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martínez-Trillos A, Casetti I, Colomer D, Pieri L, Pratcorona M, Rotunno G, Sant'Antonio E, Bellini M, Cavalloni C, Mannarelli C, Milanesi C, Boveri E, Ferretti V, Astori C, Rosti V, Cervantes F, Barosi G, Vannucchi AM, Cazzola M; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators.

Blood. 2014 Aug 14;124(7):1062-9. doi: 10.1182/blood-2014-05-578435. Epub 2014 Jul 1.

5.

Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.

Malcovati L, Papaemmanuil E, Ambaglio I, Elena C, Gallì A, Della Porta MG, Travaglino E, Pietra D, Pascutto C, Ubezio M, Bono E, Da Vià MC, Brisci A, Bruno F, Cremonesi L, Ferrari M, Boveri E, Invernizzi R, Campbell PJ, Cazzola M.

Blood. 2014 Aug 28;124(9):1513-21. doi: 10.1182/blood-2014-03-560227. Epub 2014 Jun 26.

6.

Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes.

Della Porta MG, Travaglino E, Boveri E, Ponzoni M, Malcovati L, Papaemmanuil E, Rigolin GM, Pascutto C, Croci G, Gianelli U, Milani R, Ambaglio I, Elena C, Ubezio M, Da Via' MC, Bono E, Pietra D, Quaglia F, Bastia R, Ferretti V, Cuneo A, Morra E, Campbell PJ, Orazi A, Invernizzi R, Cazzola M; Rete Ematologica Lombarda (REL) Clinical Network.

Leukemia. 2015 Jan;29(1):66-75. doi: 10.1038/leu.2014.161. Epub 2014 May 20.

PMID:
24935723
7.

Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R.

Della Porta MG, Alessandrino EP, Bacigalupo A, van Lint MT, Malcovati L, Pascutto C, Falda M, Bernardi M, Onida F, Guidi S, Iori AP, Cerretti R, Marenco P, Pioltelli P, Angelucci E, Oneto R, Ripamonti F, Bernasconi P, Bosi A, Cazzola M, Rambaldi A; Gruppo Italiano Trapianto di Midollo Osseo.

Blood. 2014 Apr 10;123(15):2333-42. doi: 10.1182/blood-2013-12-542720. Epub 2014 Feb 20.

8.

CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis.

Rumi E, Harutyunyan AS, Pietra D, Milosevic JD, Casetti IC, Bellini M, Them NC, Cavalloni C, Ferretti VV, Milanesi C, Berg T, Sant'Antonio E, Boveri E, Pascutto C, Astori C, Kralovics R, Cazzola M; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators.

Blood. 2014 Apr 10;123(15):2416-9. doi: 10.1182/blood-2014-01-550434. Epub 2014 Feb 19.

9.

Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts.

Passamonti F, Maffioli M, Cervantes F, Vannucchi AM, Morra E, Barbui T, Caramazza D, Pieri L, Rumi E, Gisslinger H, Knoops L, Kiladjian JJ, Mora B, Hollaender N, Pascutto C, Harrison C, Cazzola M.

Blood. 2014 Mar 20;123(12):1833-5. doi: 10.1182/blood-2013-12-544411. Epub 2014 Jan 17.

10.

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.

Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, Them NC, Berg T, Elena C, Casetti IC, Milanesi C, Sant'antonio E, Bellini M, Fugazza E, Renna MC, Boveri E, Astori C, Pascutto C, Kralovics R, Cazzola M; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators.

Blood. 2014 Mar 6;123(10):1544-51. doi: 10.1182/blood-2013-11-539098. Epub 2013 Dec 23.

11.

Somatic mutations of calreticulin in myeloproliferative neoplasms.

Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant'Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schönegger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R.

N Engl J Med. 2013 Dec 19;369(25):2379-90. doi: 10.1056/NEJMoa1311347. Epub 2013 Dec 10.

12.

Long term evaluation of the impact of autologous peripheral blood stem cell transplantation in multiple myeloma: a cost-effectiveness analysis.

Corso A, Mangiacavalli S, Cocito F, Pascutto C, Ferretti VV, Pompa A, Ciampichini R, Pochintesta L, Mantovani LG.

PLoS One. 2013 Sep 30;8(9):e75047. doi: 10.1371/journal.pone.0075047. eCollection 2013. Erratum in: PLoS One. 2014;9(1). doi:10.1371/annotation/949c27ad-65b0-4926-8c7b-5a45d67b1be9.

13.

MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance.

Varettoni M, Zibellini S, Arcaini L, Boveri E, Rattotti S, Pascutto C, Mangiacavalli S, Gotti M, Pochintesta L, Paulli M, Cazzola M.

Blood. 2013 Sep 26;122(13):2284-5. doi: 10.1182/blood-2013-07-513366. No abstract available.

14.

Associated cancers in Waldenström macroglobulinemia: clues for common genetic predisposition.

Morra E, Varettoni M, Tedeschi A, Arcaini L, Ricci F, Pascutto C, Rattotti S, Vismara E, Paris L, Cazzola M.

Clin Lymphoma Myeloma Leuk. 2013 Dec;13(6):700-3. doi: 10.1016/j.clml.2013.05.008. Epub 2013 Sep 24.

PMID:
24070824
15.

Serum C terminal telopeptide maintains its correlation with bone disease in patients with myeloma even under treatment with bisphosphonates.

Pochintesta L, Mangiacavalli S, Cocito F, Pompa A, Albertini R, Pascutto C, Ferretti VV, Cazzola M, Corso A.

Leuk Lymphoma. 2014 Jun;55(6):1397-8. doi: 10.3109/10428194.2013.830305. Epub 2013 Sep 3. No abstract available.

PMID:
23931337
16.

Monoclonal gammopathy of undetermined significance: a new proposal of workup.

Mangiacavalli S, Cocito F, Pochintesta L, Pascutto C, Ferretti V, Varettoni M, Zappasodi P, Pompa A, Landini B, Cazzola M, Corso A.

Eur J Haematol. 2013 Oct;91(4):356-60. doi: 10.1111/ejh.12172. Epub 2013 Aug 17.

PMID:
23859528
17.

Should cytoreductive treatment be performed before transplantation in patients with high-risk myelodysplastic syndrome?

Alessandrino EP, Della Porta MG, Pascutto C, Bacigalupo A, Rambaldi A.

J Clin Oncol. 2013 Jul 20;31(21):2761-2. doi: 10.1200/JCO.2012.48.0525. Epub 2013 Jun 17. No abstract available.

PMID:
23775971
18.

Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome.

Alessandrino EP, Porta MG, Malcovati L, Jackson CH, Pascutto C, Bacigalupo A, Teresa van Lint M, Falda M, Bernardi M, Onida F, Guidi S, Iori AP, Cerretti R, Marenco P, Pioltelli P, Angelucci E, Oneto R, Ripamonti F, Rambaldi A, Bosi A, Cazzola M; Gruppo Italiano Trapianto di Midollo Osseo (GITMO).

Am J Hematol. 2013 Jul;88(7):581-8. doi: 10.1002/ajh.23458. Epub 2013 May 30.

19.

Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms.

Rumi E, Pietra D, Guglielmelli P, Bordoni R, Casetti I, Milanesi C, Sant'Antonio E, Ferretti V, Pancrazzi A, Rotunno G, Severgnini M, Pietrelli A, Astori C, Fugazza E, Pascutto C, Boveri E, Passamonti F, De Bellis G, Vannucchi A, Cazzola M; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative.

Blood. 2013 May 23;121(21):4388-95. doi: 10.1182/blood-2013-02-486050. Epub 2013 Apr 10.

20.

Clues to pathogenesis of Waldenström macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance provided by analysis of immunoglobulin heavy chain gene rearrangement and clustering of B-cell receptors.

Varettoni M, Zibellini S, Capello D, Arcaini L, Rossi D, Pascutto C, Rattotti S, Mangiacavalli S, Pochintesta L, Gotti M, Gaidano G, Cazzola M.

Leuk Lymphoma. 2013 Nov;54(11):2485-9. doi: 10.3109/10428194.2013.779689. Epub 2013 Apr 17.

PMID:
23442064
21.

Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms.

Varettoni M, Arcaini L, Zibellini S, Boveri E, Rattotti S, Riboni R, Corso A, Orlandi E, Bonfichi M, Gotti M, Pascutto C, Mangiacavalli S, Croci G, Fiaccadori V, Morello L, Guerrera ML, Paulli M, Cazzola M.

Blood. 2013 Mar 28;121(13):2522-8. doi: 10.1182/blood-2012-09-457101. Epub 2013 Jan 25.

22.

Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma.

Mangiacavalli S, Pochintesta L, Pascutto C, Cocito F, Pompa A, Cazzola M, Corso A.

Am J Hematol. 2013 Feb;88(2):102-6. doi: 10.1002/ajh.23358. Epub 2012 Dec 8.

23.

Chronic lymphocytic leukemia with del13q14 as the sole abnormality: dynamic prognostic estimate by interphase-FISH.

Orlandi EM, Bernasconi P, Pascutto C, Giardini I, Cavigliano PM, Boni M, Zibellini S, Cazzola M.

Hematol Oncol. 2013 Sep;31(3):136-42. doi: 10.1002/hon.2032. Epub 2012 Oct 11.

PMID:
23060227
24.

A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment.

Passamonti F, Thiele J, Girodon F, Rumi E, Carobbio A, Gisslinger H, Kvasnicka HM, Ruggeri M, Randi ML, Gangat N, Vannucchi AM, Gianatti A, Gisslinger B, Müllauer L, Rodeghiero F, d'Amore ES, Bertozzi I, Hanson CA, Boveri E, Marino F, Maffioli M, Caramazza D, Antonioli E, Carrai V, Buxhofer-Ausch V, Pascutto C, Cazzola M, Barbui T, Tefferi A.

Blood. 2012 Aug 9;120(6):1197-201. doi: 10.1182/blood-2012-01-403279. Epub 2012 Jun 26.

25.

The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia.

Orlandi EM, Bernasconi P, Pascutto C.

Cancer. 2012 Oct 15;118(20):5179; author reply 5179-80. doi: 10.1002/cncr.27525. Epub 2012 Apr 17. No abstract available.

26.

Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study.

Della Porta MG, Picone C, Pascutto C, Malcovati L, Tamura H, Handa H, Czader M, Freeman S, Vyas P, Porwit A, Saft L, Westers TM, Alhan C, Cali C, van de Loosdrecht AA, Ogata K.

Haematologica. 2012 Aug;97(8):1209-17. doi: 10.3324/haematol.2011.048421. Epub 2012 Feb 7.

27.

Clinical evaluation of extra-hematologic comorbidity in myelodysplastic syndromes: ready-to-wear versus made-to-measure tool.

Della Porta MG, Ambaglio I, Ubezio M, Travaglino E, Pascutto C, Malcovati L.

Haematologica. 2012 Apr;97(4):631-2. doi: 10.3324/haematol.2011.057323. Epub 2012 Jan 22. No abstract available.

28.

Response-adjusted ISS (RaISS) is a simple and reliable prognostic scoring system for predicting progression-free survival in transplanted patients with multiple myeloma.

Corso A, Galli M, Mangiacavalli S, Rossini F, Nozza A, Pascutto C, Montefusco V, Baldini L, Cafro AM, Crippa C, Cazzola M, Corradini P.

Am J Hematol. 2012 Feb;87(2):150-4. doi: 10.1002/ajh.22220. Epub 2011 Dec 21.

29.

Similar neurotoxicity of an alternating compared to a continuous low-dose schedule of thalidomide for relapsed/refractory multiple myeloma.

Mangiacavalli S, Albani G, Caravita T, Cocito F, Pascutto C, Zappasodi P, Bringhen S, Palumbo A, Cazzola M, Corso A.

Leuk Lymphoma. 2012 Mar;53(3):514-5. doi: 10.3109/10428194.2011.600487. Epub 2011 Dec 5. No abstract available.

PMID:
22141736
30.

Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm.

Rumi E, Casetti I, Pietra D, Elena C, Ambaglio I, Pascutto C, Passamonti F, Cazzola M; AGIMM Investigators.

Am J Hematol. 2012 Jan;87(1):129-30. doi: 10.1002/ajh.22194. Epub 2011 Oct 31. No abstract available.

31.

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.

Malcovati L, Papaemmanuil E, Bowen DT, Boultwood J, Della Porta MG, Pascutto C, Travaglino E, Groves MJ, Godfrey AL, Ambaglio I, Gallì A, Da Vià MC, Conte S, Tauro S, Keenan N, Hyslop A, Hinton J, Mudie LJ, Wainscoat JS, Futreal PA, Stratton MR, Campbell PJ, Hellström-Lindberg E, Cazzola M; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium and of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative.

Blood. 2011 Dec 8;118(24):6239-46. doi: 10.1182/blood-2011-09-377275. Epub 2011 Oct 12.

32.

Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm.

Rumi E, Harutyunyan A, Elena C, Pietra D, Klampfl T, Bagienski K, Berg T, Casetti I, Pascutto C, Passamonti F, Kralovics R, Cazzola M.

Am J Hematol. 2011 Dec;86(12):974-9. doi: 10.1002/ajh.22166. Epub 2011 Sep 22.

33.

Flow-FISH evaluation of telomere length in Philadelphia-negative myeloproliferative neoplasms.

Elena C, Rumi E, Portolan M, Della Porta MG, Pascutto C, Passamonti F.

Haematologica. 2011 Aug;96(8):1236-8. doi: 10.3324/haematol.2011.047803. No abstract available.

34.

Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS).

Malcovati L, Della Porta MG, Strupp C, Ambaglio I, Kuendgen A, Nachtkamp K, Travaglino E, Invernizzi R, Pascutto C, Lazzarino M, Germing U, Cazzola M.

Haematologica. 2011 Oct;96(10):1433-40. doi: 10.3324/haematol.2011.044602. Epub 2011 Jun 9.

35.

Risk of second cancers in Waldenström macroglobulinemia.

Varettoni M, Tedeschi A, Arcaini L, Pascutto C, Vismara E, Orlandi E, Ricci F, Corso A, Greco A, Mangiacavalli S, Lazzarino M, Morra E.

Ann Oncol. 2012 Feb;23(2):411-5. doi: 10.1093/annonc/mdr119. Epub 2011 Apr 27.

PMID:
21525403
36.

Distinctive clinical and histological features of Waldenström's macroglobulinemia and splenic marginal zone lymphoma.

Arcaini L, Varettoni M, Boveri E, Orlandi E, Rattotti S, Zibellini S, Merli M, Lucioni M, Rizzi S, Gotti M, Morello L, Pascutto C, Paulli M.

Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):103-5. doi: 10.3816/CLML.2011.n.020.

PMID:
21454204
37.

Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations.

Passamonti F, Elena C, Schnittger S, Skoda RC, Green AR, Girodon F, Kiladjian JJ, McMullin MF, Ruggeri M, Besses C, Vannucchi AM, Lippert E, Gisslinger H, Rumi E, Lehmann T, Ortmann CA, Pietra D, Pascutto C, Haferlach T, Cazzola M.

Blood. 2011 Mar 10;117(10):2813-6. doi: 10.1182/blood-2010-11-316810. Epub 2011 Jan 11.

38.

The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms.

Olcaydu D, Rumi E, Harutyunyan A, Passamonti F, Pietra D, Pascutto C, Berg T, Jäger R, Hammond E, Cazzola M, Kralovics R.

Haematologica. 2011 Mar;96(3):367-74. doi: 10.3324/haematol.2010.034488. Epub 2010 Dec 20.

39.

Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.

Della Porta MG, Malcovati L, Strupp C, Ambaglio I, Kuendgen A, Zipperer E, Travaglino E, Invernizzi R, Pascutto C, Lazzarino M, Germing U, Cazzola M.

Haematologica. 2011 Mar;96(3):441-9. doi: 10.3324/haematol.2010.033506. Epub 2010 Dec 6.

40.

Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients.

Rumi E, Passamonti F, Elena C, Pietra D, Arcaini L, Astori C, Zibellini S, Boveri E, Pascutto C, Lazzarino M.

Haematologica. 2011 Mar;96(3):454-8. doi: 10.3324/haematol.2010.033779. Epub 2010 Nov 25.

41.

Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS.

Elena C, Passamonti F, Rumi E, Malcovati L, Arcaini L, Boveri E, Merli M, Pietra D, Pascutto C, Lazzarino M.

Haematologica. 2011 Jan;96(1):167-70. doi: 10.3324/haematol.2010.031831. Epub 2010 Sep 30.

42.

Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry.

Merli M, Arcaini L, Boveri E, Rattotti S, Picone C, Passamonti F, Tenore A, Sozzani L, Lucioni M, Varettoni M, Rizzi S, Morello L, Ferretti V, Pascutto C, Paulli M, Lazzarino M.

Eur J Haematol. 2010 Nov;85(5):405-15. doi: 10.1111/j.1600-0609.2010.01503.x.

PMID:
20662897
43.

A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.

Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L, Roncoroni E, Astori C, Merli M, Boggi S, Pascutto C, Lazzarino M, Cazzola M.

Leukemia. 2010 Sep;24(9):1574-9. doi: 10.1038/leu.2010.148. Epub 2010 Jul 15.

PMID:
20631743
44.

Changing pattern of presentation in monoclonal gammopathy of undetermined significance: a single-center experience with 1400 patients.

Varettoni M, Corso A, Cocito F, Mangiacavalli S, Pascutto C, Zappasodi P, Pica G, Lazzarino M.

Medicine (Baltimore). 2010 Jul;89(4):211-6. doi: 10.1097/MD.0b013e3181e763be.

45.

Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence.

Passamonti F, Rumi E, Elena C, Arcaini L, Merli M, Pascutto C, Cazzola M, Lazzarino M.

Br J Haematol. 2010 Sep;150(6):719-21. doi: 10.1111/j.1365-2141.2010.08275.x. No abstract available.

PMID:
20560961
46.

Validation of cytogenetic-based risk stratification in primary myelofibrosis.

Rumi E, Passamonti F, Bernasconi P, Arcaini L, Pietra D, Elena C, Boveri E, Pascutto C, Cazzola M, Lazzarino M.

Blood. 2010 Apr 1;115(13):2719-20. doi: 10.1182/blood-2009-12-258988. No abstract available.

PMID:
20360476
47.

Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients.

Arcaini L, Merli M, Passamonti F, Rizzi S, Ferretti V, Rattotti S, Pascutto C, Paulli M, Lazzarino M.

Br J Haematol. 2010 May;149(3):455-7. doi: 10.1111/j.1365-2141.2009.08065.x. Epub 2010 Jan 11. No abstract available.

PMID:
20064149
48.

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, Guglielmelli P, Pungolino E, Caramella M, Maffioli M, Pascutto C, Lazzarino M, Cazzola M, Tefferi A.

Blood. 2010 Mar 4;115(9):1703-8. doi: 10.1182/blood-2009-09-245837. Epub 2009 Dec 14.

49.

Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma.

Corso A, Barbarano L, Mangiacavalli S, Spriano M, Alessandrino EP, Cafro AM, Pascutto C, Varettoni M, Bernasconi P, Grillo G, Carella AM, Montalbetti L, Lazzarino M, Morra E.

Leuk Lymphoma. 2010 Feb;51(2):236-42. doi: 10.3109/10428190903452826.

PMID:
20001242
50.

Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas.

Arcaini L, Merli M, Passamonti F, Bruno R, Brusamolino E, Sacchi P, Rattotti S, Orlandi E, Rumi E, Ferretti V, Rizzi S, Meli E, Pascutto C, Paulli M, Lazzarino M.

Am J Hematol. 2010 Jan;85(1):46-50. doi: 10.1002/ajh.21564.

Supplemental Content

Loading ...
Support Center